BRAF and neoplasm: Encorafenib is a highly specific competitive inhibitor of RAF that acts solely on tumor cells expressing the BRAF V600E-mutated protein, exhibiting a more prolonged pharmacodynamic activity compared with other BRAF inhibitors.3